BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 8, 2017
View Archived Issues
Eisai updates pipeline progress of second quarter of fiscal 2017
Read More
Mitsubishi Tanabe Pharma reports development activities of second quarter of fiscal 2017
Read More
Bio-Path Holdings selects third drug candidate, gives update on discovery efforts
Read More
FDA clears IND for micro-dystrophin gene therapy program in DMD
Read More
USAN approves asalhydromorphone as nonproprietary name for KemPharm's KP-511
Read More
Clinical results encourage use of [68Ga]DATATOC for imaging neuroendocrine tumors
Read More
Novel tracer targets angiomotin for brain tumor imaging
Read More
FDA gives orphan status to Achillion's ACH-4471 for PNH
Read More
Donaperminogene seltoplasmid accepted as generic name for ViroMed's VM-202
Read More
NINJ2 gene linked to treatment response in multiple sclerosis
Read More
Memantine improves red blood cell parameters, quality of life in sickle cell patients
Read More
FDA grants orphan drug designation to arimoclomol for inclusion body myositis
Read More
KB-103 granted orphan drug designation by the FDA
Read More
GSK submits sBLA for mepolizumab as add-on to maintenance treatment of eosinophilic COPD
Read More
FDA approves Keryx's Auryxia in new indication
Read More
AstraZeneca patents new ERalpha antagonists and SERDs
Read More
Shenzhen Targetrx Biotechnology identifies PARP inhibitors
Read More
Merck & Co. presents compounds for HCV infection treatment
Read More
Novel NLRP3 agonists presented by IFM Therapeutics
Read More
Fraunhofer-Gesellschaft patents meprin inhibitors
Read More
Alnylam Pharmaceuticals begins phase III ENVISION study of givosiran
Read More
Batu Biologics receives IND approval from FDA for phase I trials of ValloVax
Read More
Appili Therapeutics wins grant from U.S. Department of Defense for antibiotic program
Read More
Kite Pharma initiates phase I study of KITE-585 in relapsed/refractory multiple myeloma
Read More
SiteOne Therapeutics receives grant from U.S. Department of Defense
Read More
DSMB clears ReNeuron's retinitis pigmentosa trial to advance into phase II
Read More
U.S. Environmental Protection Agency registers mosquito biopesticide
Read More
Seres Therapeutics awarded grant from CARB-X to support SER-155 development
Read More
Preliminary results from first in human trial of cystic fibrosis candidate GLPG-2737
Read More
Cellectar Biosciences gives update on phase I study of CLR-131 in multiple myeloma
Read More
Ultragenyx completes acquisition of Dimension Therapeutics
Read More